Search research articles
Contact Us
Filters
Showing results (41-50 of 80) with videos related to
Page
of 8
Sort By:
Journal of Affective Disorders
|
January 10, 2022
Olanzapine and samidorphan combination treatment: A systematic review
Muhammad Youshay Jawad, Yazen Alnefeesi, Leanna M W Lui, et al.
Journal of Trace Elements in Medicine and Biology : Organ of the Society for Minerals and Trace Elements (GMS)
|
November 24, 2018
Comparison of serum essential trace metals between patients with schizophrenia and healthy controls
Bing Cao, Lailai Yan, Jiahui Ma, et al.
Advances in Therapy
|
April 30, 2021
Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression
Eric P McMullen, Yena Lee, Orly Lipsitz, et al.
Journal of Psychiatric Research
|
March 11, 2021
The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review
Joshua D Di Vincenzo, Ashley Siegel, Orly Lipsitz, et al.
Journal of Psychiatric Research
|
February 4, 2021
Ecological momentary assessment of depressive symptoms using the mind.me application: Convergence with the Patient Health Questionnaire-9 (PHQ-9)
Roger S McIntyre, Yena Lee, Carola Rong, et al.
Expert Opinion on Investigational Drugs
|
April 25, 2023
Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials
Gia Han Le, Emily S Gillissie, Taeho Greg Rhee, et al.
Expert Opinion on Drug Safety
|
June 17, 2020
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence
Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Epidemiology and Psychiatric Sciences
|
February 15, 2021
The impact of COVID-19 on subthreshold depressive symptoms: a longitudinal study
Y H Liao, B F Fan, H M Zhang, et al.
Psychiatry Research
|
December 10, 2021
Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence
Joshua D Di Vincenzo, Orly Lipsitz, Nelson B Rodrigues, et al.
Expert Opinion on Drug Safety
|
April 15, 2022
Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment
Marcus A Doyle, Susan Ling, Leanna M W Lui, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 80) with videos related to
Sort By:
Page
of 8
Journal of Affective Disorders
|
January 10, 2022
Olanzapine and samidorphan combination treatment: A systematic review
Muhammad Youshay Jawad, Yazen Alnefeesi, Leanna M W Lui, et al.
Journal of Trace Elements in Medicine and Biology : Organ of the Society for Minerals and Trace Elements (GMS)
|
November 24, 2018
Comparison of serum essential trace metals between patients with schizophrenia and healthy controls
Bing Cao, Lailai Yan, Jiahui Ma, et al.
Advances in Therapy
|
April 30, 2021
Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression
Eric P McMullen, Yena Lee, Orly Lipsitz, et al.
Journal of Psychiatric Research
|
March 11, 2021
The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review
Joshua D Di Vincenzo, Ashley Siegel, Orly Lipsitz, et al.
Journal of Psychiatric Research
|
February 4, 2021
Ecological momentary assessment of depressive symptoms using the mind.me application: Convergence with the Patient Health Questionnaire-9 (PHQ-9)
Roger S McIntyre, Yena Lee, Carola Rong, et al.
Expert Opinion on Investigational Drugs
|
April 25, 2023
Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials
Gia Han Le, Emily S Gillissie, Taeho Greg Rhee, et al.
Expert Opinion on Drug Safety
|
June 17, 2020
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence
Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Epidemiology and Psychiatric Sciences
|
February 15, 2021
The impact of COVID-19 on subthreshold depressive symptoms: a longitudinal study
Y H Liao, B F Fan, H M Zhang, et al.
Psychiatry Research
|
December 10, 2021
Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence
Joshua D Di Vincenzo, Orly Lipsitz, Nelson B Rodrigues, et al.
Expert Opinion on Drug Safety
|
April 15, 2022
Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment
Marcus A Doyle, Susan Ling, Leanna M W Lui, et al.
Page
of 8